Immuno-chemo before surgery and organ-sparing treatment for throat cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Lungs & breathing, Mouth & dental clinical trials.
This trial tests whether adding immunotherapy before surgery, followed by either radiation or organ-preserving surgery, can improve outcomes for people with locally advanced laryngeal or hypopharyngeal cancer. It may help avoid complete removal of the voice box.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your cancer must be a type called squamous cell carcinoma of the larynx or hypopharynx and at a locally advanced stage.
- You must have already received a combination of chemotherapy and immunotherapy before surgery, and your main tumor must have shrunk at least partially.
- You need to be in good general health, with an ECOG performance status of 0 or 1 (able to do all activities or only light work).
- Your organ function (like blood counts, liver, and kidney) must meet specific lab results, and you must not have serious medical conditions like uncontrolled heart disease or active autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an immunotherapy drug (PD-1 inhibitor) to standard chemotherapy before surgery improves outcomes for people with advanced laryngeal or hypopharyngeal cancer. The treatment is given before your planned total laryngectomy, and the goal is to shrink the tumor and potentially improve long-term results.
This trial tests a new combination of drugs (an immunotherapy called a PD-1 inhibitor, cetuximab, and platinum chemotherapy) given before surgery for advanced throat cancer that requires removing the voice box. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial tests giving anti–PD-1 immunotherapy plus a drug called TP before surgery for oral squamous cell carcinoma (mouth/throat cancer). The goal is to see whether this pre-surgery treatment improves how much the tumor responds under the microscope.
This trial tests whether giving a combination of an immunotherapy drug (PD-1 inhibitor) and chemotherapy before surgery can help treat advanced throat cancer. The goal is to see if this approach shrinks tumors and improves outcomes.
This trial tests a new approach to treat throat cancer while trying to preserve your larynx (voice box). It combines chemotherapy drugs and an immunotherapy drug before surgery or radiation. The goal is to see if this can help you avoid needing to have your larynx removed.
This trial tests a new combination of an immunotherapy drug (adebrelimab) with chemotherapy before surgery, to shrink the cancer and improve outcomes for patients with advanced hypopharyngeal cancer. It may help make surgery more effective and reduce the chance of the cancer coming back.
Hear when a new Larynx Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.